red thread | market access’ Post

The World Orphan Drug Congress USA is now over for another year, but heeding the insights shared in Boston could yield long-term benefits for patients with rare diseases. Here are four key takeaways to achieve patient access to innovative therapies more quickly and efficiently: 💡 Involve patients actively in defining the new treatment’s value proposition, collaborating with patient organizations at the earliest opportunity. 💡 Start planning HEOR and reimbursement activities far in advance, to identify and generate the evidence package that payers will need to see. 💡 Engage with payers early and often, to educate them on the impact of the disease on patients, the unmet need, and the therapy’s clinical value. 💡 Customize reimbursement proposals to address payers’ specific uncertainties about the product’s value proposition—financial arrangements aren’t “one size fits all”! Didn’t get a chance to meet with me during the Congress? Message me here and we’ll book time to chat about ways STRATENYM can support your market access activities. #WODC #HTA #MarketAccess

In a world where 350M people are affected by a #raredisease, we have a societal obligation to address these issues.    That’s the driving force behind Chiesi Global Rare Diseases, who we are proud to represent and celebrate during this year’s #RareDiseaseWeek. 🎉 Chiesi develops treatments for a broad spectrum of rare diseases. In doing so, they let the patient voice shape who they are, establishing partnerships across industry, patient advocacy groups, and government to best support rare disease communities. Like many of our members, Chiesi is concerned about the dire societal cost of neglecting rare diseases: current estimates are up to $8.6 trillion per year. That’s why they support long-term investments in rare disease R&D: to foster economic returns AND help patient communities live their most fulfilling lives. #OneRareVoice #LifeScience #Healthcare

Unleash the potential of your rare disease solution with Trispera Pharma Solutions' Business Case report! 🚀 Navigating the rare disease market is complex, and our tailored report is your key to success. ✨ Standout Features ✨ 🌐 Real-world Insights: Benefit from expertise with insights from key opinion leaders and healthcare professionals in rare diseases, ensuring your solution aligns perfectly with patient and provider needs. 💡 Addressing Unmet Needs: Our report assesses the need for your product, offering a clear understanding of how it transforms patient care and addresses unmet medical needs. 📈 Data-Driven Success: Equip yourself with data-driven decisions for a strategic product launch, avoiding the pitfalls of unprepared journeys. 🏆 Proven Success: With a track record of success, our dedicated team has empowered numerous companies in the rare disease domain with invaluable insights, guiding them to confident and informed decisions. 🧭 Let our Business Case report be your compass, guiding you to impactful market entry and sustained success. Contact us today at info@trispera.com #RareDiseases #Trispera Discover more at www.trispera.com

Unleash the potential of your rare disease solution with Trispera Pharma Solutions' Business Case report! 🚀 Navigating the rare disease market is complex, and our tailored report is your key to success. ✨ Standout Features ✨ 🌐 Real-world Insights: Benefit from expertise with insights from key opinion leaders and healthcare professionals in rare diseases, ensuring your solution aligns perfectly with patient and provider needs. 💡 Addressing Unmet Needs: Our report assesses the need for your product, offering a clear understanding of how it transforms patient care and addresses unmet medical needs. 📈 Data-Driven Success: Equip yourself with data-driven decisions for a strategic product launch, avoiding the pitfalls of unprepared journeys. 🏆 Proven Success: With a track record of success, our dedicated team has empowered numerous companies in the rare disease domain with invaluable insights, guiding them to confident and informed decisions. 🧭 Let our Business Case report be your compass, guiding you to impactful market entry and sustained success. Contact us today at info@trispera.com #RareDiseases #Trispera Discover more at www.trispera.com.

Unleash the potential of your rare disease solution with Trispera Pharma Solutions' Business Case report! 🚀 Navigating the rare disease market is complex, and our tailored report is your key to success. ✨ Standout Features ✨ 🌐 Real-world Insights: Benefit from expertise with insights from key opinion leaders and healthcare professionals in rare diseases, ensuring your solution aligns perfectly with patient and provider needs. 💡 Addressing Unmet Needs: Our report assesses the need for your product, offering a clear understanding of how it transforms patient care and addresses unmet medical needs. 📈 Data-Driven Success: Equip yourself with data-driven decisions for a strategic product launch, avoiding the pitfalls of unprepared journeys. 🏆 Proven Success: With a track record of success, our dedicated team has empowered numerous companies in the rare disease domain with invaluable insights, guiding them to confident and informed decisions. 🧭 Let our Business Case report be your compass, guiding you to impactful market entry and sustained success. Contact us today at info@trispera.com #RareDiseases #Trispera Discover more at www.trispera.com.

Happy Rare Disease Day! I have closely witnessed the Rare Disease landscape develop over the past decade and have had the opportunity to work with clients making such life-changing products for rare disease patients. I would like to use this occasion to share some insights into some lessons we have learned working on numerous rare disease strategy and launch projects. 🌟Elevate Your Impact in Rare Disease Launches! 🌟 🚀 Supercharge Your Rare Disease Launch with Advanced Insights! Syneos has a wide range of rare disease and launch excellence offerings to support companies launching assets in rare diseases. Our latest offering aims specifically on building a holistic market understanding, measuring brand performance, and identifying areas of growth for the brand. 🌐 The Challenge: Rare disease launches demand a profound disease understanding, seamless health ecosystem connection, and a genuine grasp of the patient journey. Rise above the obstacles with our expertise! 💡 Our Solution: Our latest offering, Advanced Insights - where market intelligence meets strategy, empowers organizations to gain deep insights, enabling them to tailor their brand planning and launch strategies for more effective product launches in the rare disease space. 📈 Success Stories: Syneos helped a biopharmaceutical client understand disease area and treatment dynamics, measure brand performance, and identify areas of opportunity to inform their brand strategy and tactics in a rare disease indication. 🔗 #PharmaceuticalConsulting #RareDisease #MarketResearch #Innovation #syneoshealth

“Since launching Teva’s Pivot to Growth strategy in May 2023, we have been working on novel and expedited ways to continue to invest in our robust innovative pipeline while supporting the growth of our in-line businesses.” - Richard Francis, President and CEO of Teva From developing new therapies for Inflammatory Bowel Disease (IBD), asthma and atopic dermatitis, through building cross-sector collaborations, to identifying personalized treatment approaches using unique biomarkers (and more!), discover 7 exciting new collaborations that are currently underway at Teva, as we step up innovation and aim to better serve patients and health communities. “It’s an opportunity to truly transform the practice of medicine and change people's lives for the better,” says Richard. Because at Teva, we are all in for better health. Explore the 7 ways Teva is collaborating to innovate here: https://lnkd.in/eywK5RQV #Tevapharm #WeAreAllInForBetterHealth #Innovation #PivotToGrowth #Partnerships

Today’s 37th Workshop of the #EURORDIS Round Table of Companies saw over 130 registrants, representing 19 countries, gather to discuss the importance of transforming foresight into action to support the development of affordable and accessible treatments for rare diseases patients! 🗣️ Here are the key learnings: - Early dialogues between patients, regulators, HTA bodies, payers, and developers are key to fostering innovation. Check out our recommendation for an orphan drug development plan: https://lnkd.in/eSQWhn9Z - Mechanisms such as PRIME and MoCA are important examples of these collaborations but trust must remain at the heart of these relationships in order to foster the type of changes we want to see. - To overcome global healthcare challenges and reach the goal of 1000 new treatments by 2030, we as a community must continue to drive change and turn good will into action. Transparent public-private relationships between patient advocates, industry, academia and decision makers are essential to shape policies that best serve the interests of our community. Learn more about the ERTC on our website. Tomasz Grybek, Kevin Loth #collaboration #industry #relationships #workshop #cooperation #meeting

“Since launching Teva’s Pivot to Growth strategy in May 2023, we have been working on novel and expedited ways to continue to invest in our robust innovative pipeline while supporting the growth of our in-line businesses.” - Richard Francis, President and CEO of Teva From developing new therapies for Inflammatory Bowel Disease (IBD), asthma and atopic dermatitis, through building cross-sector collaborations, to identifying personalized treatment approaches using unique biomarkers (and more!), discover 7 exciting new collaborations that are currently underway at Teva, as we step up innovation and aim to better serve patients and health communities. “It’s an opportunity to truly transform the practice of medicine and change people's lives for the better,” says Richard. Because at Teva, we are all in for better health. Explore the 7 ways Teva is collaborating to innovate here: https://lnkd.in/gRMju9K8 #Tevapharm #WeAreAllInForBetterHealth #Innovation #PivotToGrowth #Partnerships

“Since launching Teva’s Pivot to Growth strategy in May 2023, we have been working on novel and expedited ways to continue to invest in our robust innovative pipeline while supporting the growth of our in-line businesses.” - Richard Francis, President and CEO of Teva From developing new therapies for Inflammatory Bowel Disease (IBD), asthma and atopic dermatitis, through building cross-sector collaborations, to identifying personalized treatment approaches using unique biomarkers (and more!), discover 7 exciting new collaborations that are currently underway at Teva, as we step up innovation and aim to better serve patients and health communities. “It’s an opportunity to truly transform the practice of medicine and change people's lives for the better,” says Richard. Because at Teva, we are all in for better health. Explore the 7 ways Teva is collaborating to innovate here: https://lnkd.in/gEv_9bDb #Tevapharm #WeAreAllInForBetterHealth #Innovation #PivotToGrowth #Partnerships